Literature DB >> 2578185

Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases.

M R Grafe, L S Forno, L F Eng.   

Abstract

Immunocytochemical studies of the distribution and intensity of Substance P and Met-enkephalin staining in the basal ganglia and substantia nigra were carried out in five cases each of brains from patients with Huntington's disease, Parkinson's disease, Alzheimer's disease, and normal controls. The usefulness of the peroxidase-antiperoxidase method for human autopsy material was confirmed. Substance P and Met-enkephalin fibers were distributed in essentially the same pattern as described in experimental animals and in human brains. In Huntington's disease brains decreased Substance P staining was found in the internal globus pallidus and the substantia nigra, in agreement with radioimmunoassay studies by others. Met-enkephalin staining in the external globus pallidus was of normal intensity, although present within a shrunken area. In Parkinson's and Alzheimer's diseases there was intense immunoreactivity for Substance P in the globus pallidus and substantia nigra, and for Met-enkephalin in the globus pallidus, at variance with reported decreases in Parkinson's disease by radioimmunoassay, but in essential agreement with other immunocytochemical studies. Immunocytochemical methods complement radioimmunoassays of human brain and may help in mapping neuropeptidergic pathways and in pinpointing abnormalities in these pathways in basal ganglia disorders.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578185     DOI: 10.1097/00005072-198501000-00004

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  7 in total

1.  A comparative immunohistochemical study on striatal Met-enkephalin expression in Alzheimer's disease and in progressive supranuclear palsy.

Authors:  S Matsumoto; S Goto; A Hirano
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

2.  Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.

Authors:  Jordi Bové; Jordi Serrats; Guadalupe Mengod; Roser Cortés; Eduardo Tolosa; Concepció Marin
Journal:  Exp Brain Res       Date:  2005-06-21       Impact factor: 1.972

3.  Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain.

Authors:  W S Young; T I Bonner; M R Brann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

4.  Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neurodegenerative disorders.

Authors:  S Goto; A Hirano; R R Rojas-Corona
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

Review 5.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

6.  Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study.

Authors:  M Zech; B Bogerts
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

7.  Differential loss of striatal projection neurons in Huntington disease.

Authors:  A Reiner; R L Albin; K D Anderson; C J D'Amato; J B Penney; A B Young
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.